16734-97-7Relevant academic research and scientific papers
SEROTONIN 5-HT2B INHIBITORY COMPOUNDS
-
, (2020/10/18)
The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in animals, preferably c
HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
-
Page/Page column 22, (2010/03/31)
The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases
HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
-
Page/Page column 54, (2008/06/13)
The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases
